What does the student learn regarding the role of the endothelium in clot formation?
a. The surface of the endothelium produces plasma protease inhibitors.
b. Plasma protease inhibitors assist in preventing clot formation.
c. Thrombomodulin is a protein that is converted on the surface of endothelial cells.
d. Protein A binds to thrombomodulin.
e. Activated protein C enhances the adhesion ability of neutrophils
Ans:
a. The surface of the endothelium produces plasma protease inhibitors.
b. Plasma protease inhibitors assist in preventing clot formation.
c. Thrombomodulin is a protein that is converted on the surface of endothelial cells
You might also like to view...
The nurse best maximizes an older adult's potential to avoid developing a postsurgical respiratory infection by
a. walking the patient to the bathroom in-stead of using the bedside commode. b. encouraging compliance with prescribed antibiotic therapy. c. evaluating the patient's ability to effec-tively cough and deep breathe. d. offering fluids every hour while the pa-tient is awake.
Which action represents a type of secondary cancer prevention?
A. Receiving cancer treatment with chemotherapy B. Yearly measurement of prostate-specific antigen levels C. Avoiding known cancer-causing substances or conditions D. Having genetic engineering to remove or repress oncogenes
Which of the following should you suspect?
Mr. White's son brings him in today because he notes that Mr. White has not been himself lately. He seems forgetful and has not taken care of himself as he normally does. He has reported falling twice at home to his son and has telephoned late at night because of insomnia. His blood pressure and diabetes have been difficult to control and his warfarin dosing has become more difficult. A) Alzheimer's dementia B) Alcohol use C) Urinary tract infection D) Stroke
A patient with metastatic cancer has had several fractures secondary to bone metastases. The provider orders denosumab (Xgeva). What will the nurse teach this patient?
a. Denosumab may delay healing of these fractures. b. Denosumab should be given subcutaneously every 12 months. c. Denosumab will improve hypocalcemia. d. Unlike bisphosphonates, denosumab does not increase osteonecrosis of the jaw (ONJ).